Navigation Links
Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008
Date:10/6/2008

Design Concept of Other Product - Company's Bioabsorbable Stent - Also Slated for Presentation at Symposium

HONG KONG, Oct. 6 /PRNewswire/ -- Data from multiple clinical trials of the world's first pro-healing stent, OrbusNeich's Genous Bio-engineered R stent, will be presented next week at the Transcatheter Cardiovascular Therapeutics symposium, TCT 2008, in Washington, D.C.

Robbert de Winter, M.D., Ph.D., of the Academic Medical Center in Amsterdam will provide a Genous clinical program update in an oral presentation at 4:10 p.m. EDT on Oct. 13 in Ballroom C at the Washington Convention Center. His presentation will include interim follow-up data from e-HEALING, a monitored, multi-center, worldwide (outside the United States) prospective registry with 5,000 enrolled patients.

In addition, de Winter and his colleagues will provide one-year follow-up data in an electronic poster that will be available for download and viewing throughout the convention center. Titled "One-year Clinical Outcome of a Real World Experience in Patients Treated with a Genous EPC Capturing Stent," the poster will reflect the use of the Genous stent in 236 patients who were considered to be mainly high risk in the study conducted exclusively at the Academic Medical Center.

Also scheduled for presentation in an electronic poster are one-, six- and 12-month follow-up data from studies involving acute myocardial infarction (AMI) patients at National University Hospital (NUH) in Singapore. The poster titled "The Impact of Endothelial Progenitor Cell Capture Stent Implantation in Patients with Acute Myocardial Infarction: Intermediate to Long Term Clinical Follow-Up" summarizes the studies conducted by Huay-Cheem Tan, M.D., and collaborators.

An additional electronic poster that demonstrates the clinical efficacy and safety of Genous versus a sirolimus-eluting stent and a bare metal stent in patients with ST-segment elevation myocardial infarction (STEMI) at NUH will be presented by Eric Chong, M.D. and collaborators. The poster is titled "Comparison of 24-Month Clinical Outcome of Endothelial Progenitor Cell Capture Stent versus Sirolimus-Eluting Bioabsorbable Polymer-Coated Stent versus Bare Metal Stents in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction."

Unlike drug-eluting stents, Genous, which is coated with an antibody, captures a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis.

In another oral presentation at TCT 2008, Robert Cottone, OrbusNeich's vice president of intellectual property and technologies, will describe the design concept for the company's bioabsorbable stent and its development program. Cottone's presentation will take place at 5:04 p.m. EDT on Oct. 13 in Ballroom C at the convention center.

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous Bio-engineered R stent, an antibody-coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Scoreflex(TM), Sapphire(TM), Sapphire(TM) NC, Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products to interventional cardiologists in more than 60 countries. For more information, visit http://www.OrbusNeich.com.


'/>"/>
SOURCE OrbusNeich
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2017)... , June 19, 2017  Researchers from DRUGSCAN ® ... they will host a live, complimentary webinar titled, "Untangling ... benchtop to the real world" on Wednesday June 28, ... This webinar will feature interviews with recreational ... into the manipulation techniques abusers use to prepare opioid ...
(Date:6/14/2017)... , June 14, 2017  ivWatch LLC, a ... effectiveness of intravenous (IV) therapy, is pleased to announce ... category of Nonsurgical Hospital Supplies and Equipment at the ... program for the medtech industry. The award was presented ... Jacob K. Javits Center in New York ...
(Date:6/13/2017)... , June 13, 2017 Zimmer Biomet Holdings, Inc. ... today announced that the U.S. Food and Drug Administration (FDA) ... 3, 2015 relating to its Zhejiang, China ... "The successful clearance of the Warning Letter ... manufacturing facility is a measure of the progress we have ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island Quality ... Management Alerts and Dashboards, an innovative new service enabling healthcare providers to proactively ... Management Alerts and Dashboards provide near real-time data about patients admitted to and/or ...
(Date:6/23/2017)... ... ... By scoring 100% for fiscal management and accountability, the Arthritis National Research ... Charity Navigator, validating ANRF's work as a top charity in America. , This achievement ... earns ANRF a spot on their “ 10 Charities Worth Watching ” list as ...
(Date:6/23/2017)... ... ... Studies show evidence that carotenoids and antioxidants derived either from the diet or from ... how often do ophthalmologists and optometrists in Sweden recommend the use of nutritional supplements, ... symptoms of AMD? A study published recently in Dove Medical Press journal, ...
(Date:6/23/2017)... ... June 23, 2017 , ... Dr. Ran Y. ... has recently begun offering three new minimally invasive procedures to patients who want ... reducing downtime, Dr. Rubinstein is excited to bring microneedling, microneedling facials, and platelet ...
(Date:6/23/2017)... ... 2017 , ... Everybody has their own personal preference when it comes to ... some people don't like it at all. FindaTopDoc took a look at what makes ... can give readers a taste of their deepest, darkest fantasies and has the ability ...
Breaking Medicine News(10 mins):